Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14468464 | 0.86 | TRHR (0.38) | TRHR | |
| SCHEMBL12228300 | 0.82 | TRHR (0.57) | TRHR | |
| SCHEMBL12228303 | 0.81 | TRHR (0.56) | TRHR | |
| SCHEMBL14185774 | 0.80 | TRHR (0.55) | TRHR | |
| SCHEMBL2548712 | 0.80 | CTSC (0.36) | TRHR | |
| SCHEMBL12228283 | 0.78 | TRHR (0.56) | TRHR | |
| Azetirelin SCHEMBL10703548 | 0.77 | TRHR (0.62) | TRHR | |
| Azetirelin SCHEMBL250397 | 0.77 | TRHR (0.62) | TRHR | |
| Azetirelin SCHEMBL7265691 | 0.77 | TRHR (0.62) | TRHR | |
| Azetirelin SCHEMBL4958204 | 0.77 | TRHR (0.62) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044103-B2 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | KOZIKOWSKI ALAN P | 2007-07-12 | — | — | US | disclosed |
| US-7202279-B1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | BDNF, PMP22, ADAM17 | TRHR 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.